PTGX Stock Summary and Trading Ideas (Protagonist Therapeutics | NASDAQ:PTGX)

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.

As of December 26, 2025, PTGX stock price declined to $88.78 with 374,365 million shares trading.

PTGX has a beta of -0.22, meaning it tends to be less sensitive to market movements. PTGX has a correlation of 0.00 to the broad based SPY ETF.

PTGX has a market cap of $5.52 billion. This is considered a Mid Cap stock.

Last quarter Protagonist Therapeutics reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .

In the last 3 years, PTGX traded as high as $96.54 and as low as $9.98.

The top ETF exchange traded funds that PTGX belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.

PTGX has outperformed the market in the last year with a return of +124.7%, while the SPY ETF gained +16.0%. In the last 3 month period, PTGX beat the market returning +31.7%, while SPY returned +4.6%. However, in the most recent 2 weeks PTGX has underperformed the stock market by returning -6.9%, while SPY returned +1.5%.

PTGX support price is $86.81 and resistance is $90.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX shares will trade within this expected range on the day.